Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use

Figure 12

D35-dAs40, D35core-dAs40, and D35-SPG showed better adjuvanticity with influenza SV vaccine in cynomolgus monkeys. (a) Immunization and assay schedule. Six groups of monkeys ( or 3) were immunized with SV vaccine (A/New Caledonia/20/99, 5 μg/head) s.c. in a total volume of 500 μL with or without the indicated adjuvants (4.7 nmol each: K3; 30 μg, D35; 30 μg, D35-dAs40; 92 μg, D35-SPG; 92 μg as D35-dAs40 amount) twice in 2-week intervals. (b) Anti-SV total IgG in sera was determined by ELISA. -axis indicates the serum dilutions. Each line indicates an individual monkey. (c) In a separate experiment, two groups of monkeys () were immunized with D35 (4.7 nmol = 30 μg) or D35core-dAs40 (4.7 nmol = 80 μg) as in (a). Four weeks after the first immunization, anti-SV total IgG titers were determined by ELISA. Bar indicates the mean ± SEM.

(a)

(b)

(c)